Platelet survival determined with 51Cr versus 111In

Area of Science:

• Nuclear Medicine
• Hematology
• Immunology

Background:

• Platelet survival studies are crucial for diagnosing and managing thrombocytopenic disorders.
• Previous research has utilized various radiolabels, with 51Cr being a common choice.
• The introduction of 111In-oxine offered potential advantages for in vitro platelet labeling.

Purpose of the Study:

• To determine optimal in vitro labeling conditions for human platelets using 111In-oxine.
• To comparatively evaluate platelet mean life span (MLS) and sequestration sites using 51Cr and 111In labels.
• To assess the utility of 111In-oxine in patients with autoimmune thrombocytopenic purpura (AITP) and other thrombocytopenic conditions.

Main Methods:

• Optimized in vitro labeling of human platelets with 111In-oxine.
• Comparative evaluation of MLS and sequestration sites in 79 patients using 51Cr (n=26) and 111In (n=53) labels.
• Patient subgrouping based on clinical criteria: AITP, hypersplenism, impaired thrombopoiesis, unclassified thrombocytopenia, and non-thrombocytopenic controls.

Main Results:

• No statistically significant difference in MLS between 51Cr and 111In labels in AITP (18.6h vs 17.3h) and hypersplenism (94.7h vs 122.3h) groups.
• Significant correlation between MLS and platelet counts in AITP patients for both labels (P<0.001).
• 111In showed a trend towards higher 15-minute recovery, significant in AITP (P<0.05); sequestration sites were similar for both labels.

Conclusions:

• Platelet survival studies yield comparable results using both 51Cr and 111In methods, contrary to some previous reports.
• 111In-oxine offers distinct advantages for platelet labeling and kinetics investigation.
• 111In is the recommended label of choice for platelet survival and kinetic studies due to its benefits.